Mechanistically, αPD‐1 activation promotes the expansion of CD8 T cells,[25, 50] and modulation of CD11b induces a change in the immune cell population by reducing the number of immunosuppressive cells while establishing a more proinflammatory TME.[11, 16] Consistent with our data, ADH‐503 treatment does not affect the viability of tumor or stromal cells.[16] Stromal cells showed a slight increase in metabolic activity and DNA content upon immunomodulatory treatment, confirming the effective modulation of the immune cell compartment in response to ADH‐503 treatment in our 3D model. This evidence concerns the gene ITGAM and neoplasm.